Document › Details
Orexo AB. (8/31/11). "Press Release: Orexo Appoints Carl-Johan Blomberg as New Chief Financial Officer". Uppsala.
Orexo AB (STO: ORX) appoints Carl-Johan Blomberg as new Chief Financial Officer, effective September 1. Carl-Johan Blomberg will take overall responsibility for the Group's Finance and Administration function, including IR and IT and will be part of the executive management team.
Carl-Johan has many years extensive experience in Finance from various industries, such as engineering, electronics and pharmaceuticals. Most recently he held the position of CFO at Micronic Mydata, and has earlier held Financial Director positions within Alfa-Laval, Procordia and Pharmacia & Upjohn.
"We are very pleased with the recruitment of Carl-Johan as our new CFO. He brings broad experience and will play a key role in the future development of Orexo," says Anders Lundström, President and CEO of Orexo AB.
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66
Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo's registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. More information can be found at www.orexo.com.
Orexo AB (publ) discloses the information provided in this press release pursuant to the Securities Markets Act. The information was provided for public release on August 31, 2011 at 11:15a.m. CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.
Record changed: 2012-03-12
More documents for Orexo (Group)
-  Orexo AB. (8/6/14). "Press Release: OX-MPI Project Returned to Orexo". Uppsala....
-  Orexo AB. (10/23/13). "Press Release: Interim Report January–September 2013"....
-  Kibion. (11/23/12). "Press Release: Diabact UBT + IRIS – the Perfect Combination for Helicobacter pylori Diagnosis. Comparison IRIS – Mass Spec"....
-  Orexo AB. (3/6/12). "Press Release: Orexo AB Focuses Its Business and Reduces Costs". Uppsala....
-  Orexo AB. (10/4/11). "Press Release: Orexo Appoints Peter Edman as Chief Scientific Officer". Uppsala....
-  Orexo AB. (9/16/11). "Press Release: Orexo Strengthens Its Commercial Knowhow and Appoints Nikolaj Sørensen as Chief Commercial Officer". Uppsala....
-  Orexo AB. (7/14/11). "Press Release: Orexo Takes Leading Position in Diagnostic Breath Tests through Acquisition". Uppsala....
-  Orexo AB. (1/13/11). "Press Release: Anders Lundström to Be the New CEO of Orexo". Uppsala....
-  Boehringer Ingelheim. (12/16/10). "Press Release: Boehringer Ingelheim and Orexo Report Progress in Their Pain and Inflammatory Diseases Collaboration". Uppsala & Ingelheim....
-  Orexo AB. (10/27/10). "Press Release: Orexo Strengthens Its Subsidiary Kibion by Recruiting Petter Bäckgren as CEO". Uppsala....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to email@example.com and simply fill the subject line with the word »LSE newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)